Back to top

crispr: Archive

Zacks Equity Research

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

VRTXPositive Net Change CPRXPositive Net Change CRSPPositive Net Change CSTLNegative Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

VRTXPositive Net Change AGENPositive Net Change INOPositive Net Change CRSPPositive Net Change